Clomifene Citrate
Phase 3Small molecule
Clomifene Citrate is one of 33 small molecule programs targeting Azoospermia. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Ovarian Reserve
#DrugCompanyPhaseTrials
1Ulipristal Acetate
AbbVieApproved
Folvite
Eli LillyPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Ovitrelle
Merck & Co.Approved
Buserelin
NNCIC Clinical Trials Group
Approved
Human Menopausal Gonadotropin
EMD SeronoApproved
Dehydroepiandrosterone
IInflabloc Pharmaceuticals
Phase 3
Trelstar
OOncoVerity, Inc.
Phase 2
Myoinositol
SSohag University
Phase 3
Dienogest
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CLE1 trial
Azoospermia1 trial
Ovarian Reserve1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clomifene Citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Nottingham